From: Vitamin C revisited
Study | Design | Intervention | Number of patients | Incidence of new POAF (%) | Pvalue | Other clinical benefits |
---|---|---|---|---|---|---|
Dingchao and colleagues [101] | Controlled; patients undergoing cardiopulmonary bypass | i.v. vitamin C; 250 mg/kg i.v. before | 45 | MDA ↓; CK, CK-MB ↓; postbypass defibrillation 0 vs. 12.5 %; CI ↑, LOS ICU ↓, LOS hospital ↓ | ||
Control | 40 | |||||
Carnes and colleagues [82] | Matched control; CABG | Oral vitamin C; 2 g night before, 500 mg daily for 5 days | 43 | 16.3 | 0.048 | |
Matched control | 43 | 34.9 | ||||
Eslami and colleagues [98] | RCT; CABG | β-Blocker + oral vitamin C; 2 g night before, 1 g twice daily for 5 days | 50 | 4 | 0.002 | |
β-Blocker alone | 50 | 26 | ||||
Bjordahl and colleagues [99] | RCT; CABG | Oral vitamin C; 2 g night before, 1 g twice daily for 5 days | 89 | 30.3 | 0.985 | Shorter time on ventilator, 1.2 vs. 1.4 days, P = 0.032 |
Placebo | 96 | 30.2 | ||||
Papoulidis and colleagues [100] | RCT; CABG | i.v. vitamin C; 2 g 3 hours before CPB | 85 | 44.7 | 0.041 | Time to SR conversion ↓, LOS hospital ↓, LOS ICU ↓ |
i.v. saline | 85 | 61.2 | ||||
Rodrigo and colleagues [95] | RCT | Preoperative PUFA; 2 g/day for 5 days; vitamin C 1 g/day + vitamin E 400 IU/day for 2 days preoperatively and postoperatively until discharge | 103 | 9.7 | <0.001 | Oxidative stress-related biomarkers in atrial tissue ↓ |
Placeboa | 100 | 32 |